Ranbaxy Laboratories Ltd., a subsidiary of Daiichi Sankyo Co., Ltd., has taken actions to address past conduct under prior management to address and correct the conduct that led to the investigations by the U.S. Department of Justice (DOJ) and the U.S. FDA. These efforts include significant changes to Ranbaxy’s management, culture, operations and compliance.   According to a company statement, Daiichi Sankyo believes that certain former shareholders of Ranbaxy concealed and misrepresented ...